Advertisement
Canada markets open in 8 hours 35 minutes

  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CAD/USD

    0.7318
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    79.16
    +0.21 (+0.27%)
     

  • Bitcoin CAD

    81,426.99
    +3,086.77 (+3.94%)
     

  • CMC Crypto 200

    1,283.18
    +12.44 (+0.98%)
     

  • GOLD FUTURES

    2,314.80
    +5.20 (+0.23%)
     

  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • NASDAQ futures

    17,753.25
    +103.50 (+0.59%)
     

  • VOLATILITY

    14.68
    -0.71 (-4.61%)
     

  • FTSE

    8,172.15
    +50.91 (+0.63%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6815
    -0.0002 (-0.03%)
     

Eastwood Bio-Medical Canada First Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2023)

editorial-team@simplywallst.com (Simply Wall St)
·1 min read

Eastwood Bio-Medical Canada (CVE:EBM) First Quarter 2024 Results

Key Financial Results

  • Revenue: CA$201.0k (down 40% from 1Q 2023).

  • Net loss: CA$54.2k (loss narrowed by 22% from 1Q 2023).

  • CA$0.001 loss per share (in line with 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eastwood Bio-Medical Canada shares are up 10.0% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Eastwood Bio-Medical Canada (including 4 which don't sit too well with us).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.